Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease.

Eileen CrowleyChristopher MaMarija AndicBrian G FeaganAnne M GriffithsVipul Jairath

Published in: Journal of Crohn's & colitis (2021)

Five drugs are currently approved for use in the paediatric IBD population, with long interval delays after adult approval. The impact of these drug development processes in paediatric IBD is awaited. Further consideration needs to be given to the age of enrollment along with novel, more efficient trial designs in an effort to improve access for paediatric IBD patients to newer therapies.

Keyphrases

intensive care unit
emergency department
end stage renal disease
ulcerative colitis
drug administration
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
study protocol
healthcare
health insurance
drug induced